Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 27, shares of Erasca dropped sharply after Revolution Medicines Inc. (NASDAQ:RVMD) accused the company of infringing patents and misusing trade secrets tied to its cancer drug candidate ERAS-0015. Revolution claims the therapy is substantially similar to its own treatment and demanded that Erasca halt U.S. development, also alleging improper use of comparative data. While Erasca disputes the claims and plans to fight them, the dispute overshadowed positive early-stage trial results for ERAS-0015 and triggered a steep selloff in the stock.
On April 23, Mizuho reiterated an Outperform rating on Revolution Medicines Inc. shares (NASDAQ:RVMD) and raised the price target to $185 from $140.
The price target hike comes amid growing confidence about the company’s lead candidate drug, daraxonrasib, in the treatment of pancreatic cancer. The research firm has already increased the drug’s success probability to 90% from 80%, buoyed by recent clinical trial data. It has also accelerated the drug’s adoption trajectory as a first- and second-line treatment for pancreatic cancer.
Immediate first-line data showed landmark analyses at 6 months for the daraxonrasib regimen that were comparable to those of gemcitabine plus nab-paclitaxel. Mizuho remains optimistic about the ongoing RaSolute 303 study following daraxonrasib’s performance as a second-line treatment. It expects the drug to generate $14 billion in risk-adjusted pancreatic cancer revenues by 2035.
Revolution Medicines Inc. (NASDAQ:RVMD) is a clinical-stage oncology company. It develops targeted therapies for patients with RAS-addicted cancers, which drive roughly 30% of human cancers. The company uses a proprietary tri-complex inhibitor platform to target active RAS proteins (RAS-ON inhibitors).
While we acknowledge the potential of RVMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 11 Best TSX Stocks to Buy According to Hedge Funds and 8 Best Australian Stocks to Buy in 2026.
Disclosure: None. Follow Insider Monkey on Google News.